Company TxCell CBOE EUROPE EQUITIES
Equities
0QTN
FR0010127662
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Business Summary
TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Managers
Managers | Title | Age | Since |
---|---|---|---|
Caroline Courme
IRO | Public Communications Contact | - | 29/02/16 |
Corporate Officer/Principal | - | - | |
Matthieu Allez
PRN | Corporate Officer/Principal | - | - |
Bernard Malissen
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | 61 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Duncan Mckay
CHM | Chairman | - | 11/02/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 23,195,394 | 1,045,009 ( 4.505 %) | 0 | 4.505 % |
Company contact information
Sangamo Therapeutics France SAS
Les Cardoulines HT1 Allée de la Nertière
06560, Valbonne
+33 4 97 21 83 00
http://txcell.com/Sector
1st Jan change | Capi. | |
---|---|---|
+16.49% | 122B | |
+19.69% | 115B | |
+21.22% | 26.64B | |
-23.60% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.52% | 15.49B | |
+63.44% | 14.83B | |
+2.21% | 13.67B |
- Stock Market
- Equities
- TXCL Stock
- 0QTN Stock
- Company TxCell